Vagus nerve stimulation (VNS) has been FDA-approved for drug-resistant epilepsy since 1997, making it one of the longest-running neuromodulation therapies in clinical use. But “FDA-approved” and “works well for everyone” are different claims. The clinical evidence shows a therapy that helps many people significantly, rarely produces seizure freedom, and improves over time in ways that initially surprised researchers. Understanding the real outcome data helps set appropriate expectations.
The Pivotal Trial Data
VNS approval was based on the E03 and E05 randomised controlled trials conducted in the 1990s. These compared high-stimulation VNS against low-stimulation (active control) in patients with drug-resistant epilepsy. At three months, approximately 28% of high-stimulation patients achieved a 50% or greater reduction in seizure frequency, compared to about 15% in the low-stimulation group. The difference was statistically significant but modest — VNS was clearly not a dramatic cure.
These numbers initially positioned VNS as a useful but limited adjunctive therapy. What changed the clinical perspective was the long-term follow-up data.
The Long-Term Improvement Pattern
Unlike most epilepsy treatments, which show their maximum effect early and may lose efficacy over time, VNS appears to become more effective with continued use. A 2016 meta-analysis by Englot and colleagues found that responder rates (50% or greater seizure reduction) increased from approximately 33% at four months to 44% at one year and around 50-60% at two to three years of continuous therapy.
The mechanism behind this progressive improvement isn’t fully understood but likely involves neuroplastic changes — gradual remodelling of neural circuits through sustained electrical input. The vagus nerve projects to the nucleus tractus solitarius, which connects to widespread brain regions including the locus coeruleus (norepinephrine), raphe nuclei (serotonin), and limbic structures. Chronic modulation of these networks may produce cumulative effects that acute stimulation cannot.
Complete seizure freedom remains uncommon — approximately 5-8% of patients become seizure-free with VNS alone. Most patients who benefit still have seizures, but fewer and often less severe. For many families dealing with drug-resistant epilepsy, a 50-75% seizure reduction represents a meaningful quality-of-life improvement even without complete freedom.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Who Responds Best
Predicting who will respond well to VNS remains one of the therapy’s challenges. Several patterns have emerged from retrospective analyses: younger patients tend to have better response rates, generalised epilepsy may respond somewhat better than focal epilepsy in some studies, and shorter duration of epilepsy before VNS implantation correlates with better outcomes — though this finding isn’t consistent across all data sets.
Patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex have shown meaningful responses in case series, making VNS a consideration for these difficult-to-treat populations. However, no reliable biomarkers predict individual response before implantation, so the decision involves informed risk-benefit discussion rather than certainty.
VNS Compared to Other Neuromodulation Options
For patients with a clearly identifiable seizure focus, resective surgery (removing the brain region generating seizures) remains the gold standard, with seizure freedom rates of 60-70% for temporal lobe epilepsy. VNS is typically considered when patients are not candidates for resection — when no single focus can be identified, when the focus is in eloquent cortex, or when previous surgery has failed.
Two newer neuromodulation alternatives now compete with VNS. Responsive neurostimulation (RNS, NeuroPace, FDA-approved 2013) uses intracranial electrodes to detect seizure onset patterns and deliver targeted stimulation in real time — a closed-loop approach. Median seizure reduction is approximately 53% at one year and improves to around 66-75% at longer follow-up, with some patients achieving seizure freedom. However, RNS requires intracranial electrode placement, carries higher surgical risk, and works best when one or two seizure foci can be identified.
Deep brain stimulation (DBS) targeting the anterior thalamic nucleus (SANTE trial, FDA-approved 2018) showed approximately 40% median seizure reduction at one year, increasing to about 69% at five years. Like RNS, it requires intracranial surgery. Both newer therapies show the same progressive improvement pattern as VNS, suggesting this may be a general feature of chronic neuromodulation rather than specific to any one approach.
Side Effects and Quality of Life
LivaNova manufactures current VNS systems. The AspireSR (2015) introduced autostimulation — detecting heart rate increases that often accompany seizures and delivering additional stimulation bursts automatically. The SenTiva (2017) added programmability features and smaller size. These responsive features represent a move toward closed-loop VNS, though the detection method (cardiac rather than neural) is less specific than RNS’s direct brain recording.
Side effects remain consistent across device generations: hoarseness or voice change during stimulation periods (reported in up to 66% of patients, usually mild), cough, throat discomfort, and occasionally shortness of breath. These typically diminish over the first months. The stimulation can be felt as a tingling in the throat. Unlike anti-epileptic drugs, VNS doesn’t cause cognitive dulling, sedation, or weight changes — a significant quality-of-life advantage for many patients.
Setting Realistic Expectations
VNS works best when framed honestly: it’s an adjunctive therapy that reduces seizure burden in roughly half of patients over time, rarely produces seizure freedom, and carries relatively low surgical and side-effect risk compared to intracranial alternatives. For patients who aren’t surgical resection candidates and haven’t achieved adequate control with medications, VNS offers a meaningful option with a nearly 30-year track record. The progressive improvement pattern means that early results shouldn’t be taken as final — many patients who show modest initial benefit go on to achieve clinically significant reductions over the first two to three years.
Want to understand how vagus nerve stimulation works, what the devices actually do, and the broader science of vagal modulation? Get the Vagus Nerve & Me eBook for a comprehensive guide to VNS technology and the vagus nerve’s role in neurological health.
